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Introduction
Neuroleptic malignant syndrome (NMS) is an emergent, often
fatal, medical condition associated with the use of dopamine
receptor antagonist medications.1,5 Hyperthermia, muscle
rigidity, autonomic instability, evidence of muscle injury, and
altered mental status are known to be the hallmarks of the
disease2. In contrast with the typical presentation, atypical
NMS presents with a different set of symptoms, making
diagnosis difficult.2 It is important to use clinical acumen to
make a timely and efficient diagnosis of NMS. We present a
case of Atypical NMS in a 21 year old male.

Clinical Case

Discussion

A 21-year-old African American male with previous psychiatric
history of “schizophrenia, bipolar disorder, acute dystonia, and
tardive dyskinesia” was transferred to the emergency
department from county jail, where he was being held for
disturbing the peace, and assault. He was brought to the ED
with a history of 2 to 3 days of decreased activity, not eating,
drooling, “howling”, and altered mental status. During this time
patient was in isolation for previously erratic behavior.
Conversations with staff at jail state that he was tachycardic
and hypertensive at times during this episode yet when asked
for full records they declined and explained they “don’t keep”
charts or records. Jail nurses were able to tell us his
medications include haloperidole decanoate, oral haloperidole
and trihexylphenidyl yet he had been refusing medications in
recent days to weeks. They were unable to provide
information regarding PRN medications given during this
period of time. On admission vital signs were as follows: BP
128/80, HR 113, Temp. 97.6, RR 20, O2 Sat. 99%. He
expressed much pain and immobility. He was able to
communicate with small head movements, grunts, and finger
movements. Exam showed posturing, bradykinesia, trismus,
sialorrhea, diaphoresis, and urinary incontinence. Lab findings
indicated elevated creatinine kinase of 18,963 IU/L, WBC of
14.2 x10^9/L, AST 330 IU/L, and ALT 98 IU/L. Iron studies
showed the following: iron 42 mcg/dL, ferritin 293 ng/mL, iron
sat 20%, transferrin 168 mg/dL, TIBC 213 mcg/dL. CT of head
was unremarkable. Throughout the hospitalization he
displayed no cogwheeling, no muscle rigidity, no
hyperthermia, and no obvious cognitive dulling. He did not
respond to 2mg lorazepam IV nor 10mg diazepam q8hrs IV for
1 ½ days. Due to components of the history and physical
exam, laboratory and imaging studies, it was determined that
this patient was presenting with atypical NMS and
bromocriptine therapy was initiated. The patient steadily
improved back to baseline over a 22 day admission.

It is essential to recognize NMS to prevent associated
mortality. Mortality rates of unrecognized NMS are estimated
to be 10%-20%.3 The presentation of NMS may vary
significantly, making the diagnosis difficult to ascertain;
however, key lab values are of diagnostic value. Initially, the
differential included NMS, catatonia, and anticholinergic
delirium. Catatonia was a less likely diagnosis as lorazepam
2mg IV push demonstrated no improvement of symptoms.
Anticholinergic delirium usually presents with altered mental
status rather than movement disorder. CK and AST were
elevated due to sustained muscle rigidity and
rhabdomyolysis, this supports the diagnosis of NMS.7 Serum
iron levels below 55.8 mcg/dL is also associated with NMS. 4
Low serum iron concentration is an acute phase reactant in
NMS and acts as a helpful adjunctive biochemical marker.4
The presentation of NMS may be insidious over days. Most
cases present within 3 days, though some may be up to 30
days. The patient was treated with bromocriptine and there
was significant improvement. Once diagnosis is made,
antipsychotic medications should be held and re-challenging
the patient with an antipsychotic can occur after a 5-14 day
washout period from symptoms. Our patient was started on
aripiprazole and titrated up to 15mg TID.
In conclusion, NMS can present with a variety of
symptoms. Recognizing atypical presentations of NMS is very
important. Several sources propose various characteristic
symptoms of atypical NMS including tremor, sialorrhea,
akinesia, dystonia, trismus, myoclonus, dysarthria, dysphagia,
diaphoresis, urinary incontinence, pallor, elevated CPK,
leukocytosis, low serum iron, and elevated liver enzymes,
often but not always associated with the classic features.1-4
Our patient exhibited many of the proposed characteristics of
NMS (posturing, bradykinesia, trismus, sialorrhea,
diaphoresis, and urinary incontinence) yet he did not present
with any of the “hallmark” features. The elevated creatine
kinase, leukocytosis, transaminitis, and iron studies were
helpful in making the diagnosis.

